Sugi Predict

Sugi Predict / Compounds / SCHEMBL171832

SCHEMBL171832

SCHEMBL171832

Cc1ccc(OCC(N)=O)cc1

nearest known ligand 0.66

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ WDR5 P61964 1/20 0.66
▸ HPGD P15428 3/20 0.58
▸ MAPT P10636 3/20 0.58
▸ LMNA P02545 1/20 0.56
▸ GAA P10253 1/20 0.56
▸ PARP10 Q53GL7 1/20 0.54
▸ NPC1 O15118 2/20 0.54
▸ RAB9A P51151 1/20 0.54
▸ L3MBTL1 Q9Y468 3/20 0.53
▸ TDP1 Q9NUW8 2/20 0.53
▸ ALDH1A1 P00352 1/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ HDAC1 Q13547 1/20 0.50
▸ POLB P06746 1/20 0.50
▸ BLM P54132 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10506137 0.89 MEN1 (0.58) HPGDMAPTPARP10RAB9ATDP1
SCHEMBL20330018 0.83 L3MBTL1 (0.54) WDR5HPGDMAPTLMNAGAA
SCHEMBL6377733 0.83 PARP10 (0.66) MAPTLMNAPARP10NPC1TDP1
SCHEMBL9811886 0.83 MEN1 (0.50) WDR5HPGDMAPTPARP10RAB9A
SCHEMBL1031505 0.83 MAPT (0.58) HPGDMAPTLMNAGAAPARP10
SCHEMBL11425674 0.83 MAPT (0.61) WDR5HPGDMAPTLMNAGAA
SCHEMBL20234842 0.82 L3MBTL1 (0.53) WDR5HPGDMAPTLMNAGAA
Hydrochloric Acid SCHEMBL8781907 0.82 MAPT (0.57) HPGDMAPTLMNAGAAPARP10
SCHEMBL11067706 0.81 WDR5 (0.58) WDR5HPGDMAPTLMNAGAA
SCHEMBL11126183 0.81 MAPT (0.59) WDR5HPGDMAPTLMNAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4384027-A1 COMPOSITION COMPRISING A NUTRIENT AND A TASTE MODULATOR Firmenich SA (CH) 2024-06-19 — — EP claimed
WO-2023072604-A1 COMPOSITION COMPRISING A NUTRIENT AND A TASTE MODULATOR FIRMENICH SA (CH) 2023-05-04 — — WO claimed
CN-108853105-B Cosmetic composition, pharmaceutical composition and food composition 西姆莱斯股份公司 2021-10-15 — — CN claimed
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same CEPHALON, INC. (US) 2011-06-16 — — US claimed
US-7915236-B2 Proteasome inhibitors and methods of using the same CEPHALON, INC. (US) 2011-03-29 — — US claimed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 — — EP claimed
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2009-11-26 — — US claimed
EP-1660507-B1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2009-08-05 — — EP claimed
CN-1867572-A proteasome inhibitors and methods of use thereof CEPHALON INC (US) 2006-11-22 — — CN claimed
EP-1660507-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2006-05-31 — — EP claimed
US-20050107307-A1 Proteasome inhibitors and methods of using the same TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-19 — — US claimed
WO-2005021558-A2 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON, INC. (US) 2005-03-10 — — WO claimed
WO-2025078256-A1 COMPOSITION GIVAUDAN SA (CH) 2025-04-17 — — WO disclosed
US-20230346812-A1 METHODS FOR TREATING SARS COV-2 INFECTIONS GILEAD SCIENCES, INC. 2023-11-02 — — US disclosed
US-11660307-B2 Methods for treating SARS CoV-2 infections GILEAD SCIENCES, INC. (US) 2023-05-30 — — US disclosed
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS GILEAD SCIENCES, INC. 2023-04-27 — — US disclosed
US-4840882-A CONTAINING A VINYL SULFONYL HARDENER KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1989-06-20 — — US disclosed
US-4329454-A Cephalosporin compounds ELI LILLY AND COMPANY (US) 1982-05-11 — — US disclosed
US-4144391-A REPLACING AN ACETOXY GROUP BY A SULFUR NUCLEOPHILE ELI LILLY AND COMPANY (US) 1979-03-13 — — US disclosed
US-4031084-A Process for cephalosporin antibiotic intermediates ELI LILLY AND COMPANY (US) 1977-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291918-A1 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME PSMB11, PSMB5, PSMB6 WDR5 1023/4885HPGD 3107/4885MAPT 2121/4885
US-20050107307-A1 Proteasome inhibitors and methods of using the same PSMB11, PSMB5, PSMB6 WDR5 1023/4885HPGD 3107/4885MAPT 2121/4885
US-20230125751-A1 METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS PNP, RPIA, HPRT1 WDR5 3076/4885HPGD 1175/4885MAPT 4472/4885
US-11660307-B2 Methods for treating SARS CoV-2 infections ACE2, ACE, PNP WDR5 2950/4885HPGD 1777/4885MAPT 2507/4885
US-20110144033-A1 Proteasome Inhibitors and Methods of Using the Same PSMB11, PSMB5, PSMB6 WDR5 1023/4885HPGD 3107/4885MAPT 2121/4885
US-20230346812-A1 METHODS FOR TREATING SARS COV-2 INFECTIONS ACE2, ACE, PNP WDR5 2950/4885HPGD 1777/4885MAPT 2507/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.